Emergent BioSolutions to Release Second Quarter 2023 Financial Results and Conduct Conference Call on August 8, 2023
GAITHERSBURG, Md. , July 25, 2023 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Tuesday, August 8, 2023 , at 5:00 pm eastern time to discuss the...
Emergent BioSolutions Receives U.S. FDA Approval of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted), previously known as AV7909, a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use
Emergent has been delivering CYFENDUS™ vaccine to the U.S. Department of Health and Human Services since 2019, under pre-Emergency Use Authorization status, and will continue to work with the U.S....
Emergent BioSolutions Announces CEO Transition
Robert G. Kramer Sr . to Retire Haywood Miller to Serve as Interim CEO GAITHERSBURG, Md. , June 27, 2023 (GLOBE NEWSWIRE) — Emergent BioSolutions (NYSE: EBS, “Emergent” or the...
Emergent BioSolutions Finalizes Sale of Travel Health Business to Bavarian Nordic
GAITHERSBURG, Md. , May 15, 2023 (GLOBE NEWSWIRE) — Emergent BioSolutions (NYSE: EBS) today announced it has completed the sale of its travel health business to Bavarian Nordic (OMX: BAVA). At...
Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 25, 2023 at 9:00am EDT
GAITHERSBURG, Md. , May 11, 2023 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) announced today that its 2023 Annual Meeting of Stockholders will be held in a virtual-only format via...
Emergent BioSolutions Reports Financial Results For First Quarter 2023
Reports Q1 2023 total revenues of $165M , above the prior guidance range, net loss of $183M and adjusted EBITDA of negative $101M Updates FY 2023 guidance and provides initial Q2 2023 guidance...
Emergent BioSolutions to Release First Quarter 2023 Financial Results and Conduct Conference Call on May 9, 2023
GAITHERSBURG, Md. , April 19, 2023 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Tuesday, May 9, 2023 , at 5:00 pm eastern time to discuss the...
U.S. FDA Approves Over-the-Counter Designation for Emergent BioSolutions’ NARCAN® Nasal Spray, a Historic Milestone for the Opioid Overdose Emergency Treatment
NARCAN ® Naloxone HCl Nasal Spray 4 mg is currently the first and only prescription strength naloxone nasal spray to receive over-the-counter status in the U.S. , which is a critical step toward...
Emergent BioSolutions Reports Financial Results for Fourth Quarter 2022
Reports Q4 2022 total revenues of $331M resulting in FY 2022 total revenues of $1,121M , in line with prior guidance Reports Q4 2022 net loss of $88M and FY 2022 net loss of $224M Reports Q4 2022...
Emergent BioSolutions Reports FDA Advisory Committees’ Unanimous Vote in Favor of NARCAN® (naloxone HCI) Nasal Spray for Over-the-Counter Use
If approved by the FDA, NARCAN Nasal Spray will be the first 4 mg naloxone nasal spray switched from prescription status to over-the-counter use GAITHERSBURG, Md. , Feb. 15, 2023 (GLOBE NEWSWIRE)...
Emergent BioSolutions Announces Sale of Travel Health Business to Bavarian Nordic for Up To $380 Million
GAITHERSBURG, Md. , Feb. 15, 2023 (GLOBE NEWSWIRE) — Emergent BioSolutions (NYSE: EBS) today announced that it has entered into an agreement to sell its travel health business to Bavarian...
Emergent BioSolutions to Release Fourth Quarter 2022 Financial Results and Conduct Conference Call on February 27, 2023
GAITHERSBURG, Md. , Feb. 06, 2023 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Monday, February 27, 2023 , at 5:00 pm eastern time to discuss the...